Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS
Ionis-Partnered Asset Developed For SOD1 Genetic Mutations
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.
You may also be interested in...
Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.
After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?
Company seeks accelerated approval based on changes in neurofilament as a surrogate for efficacy; with controversy over FDA’s Aduhelm approval in Alzheimer’s still raging, agency is again faced with deciding whether biomarker data in a neurodegenerative disease with high unmet need are sufficient to justify approval in the face of a failed clinical endpoint study.